Phase II and Phase III Catalyst Monitor: Q3 2025 Outlook Report - Upcoming FDA Decisions Drive Momentum in Biopharma with Key Catalysts Across GHD, PKU, Presbyopia, and Wet AMD Treatments

Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q3 2025 Outlook" report has been added to ResearchAndMarkets.com's offering.The report delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, top-line results, regulatory filings, PDUFA dates, and expected approvals. The report covers 18 significant catalyst events that are expected to occur in Q3 2025. Some of the catalysts covered in the report, include FDA app ...